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Endothelin-1 and endothelin B type receptor are induced in mesangial
proliferative nephritis in the rat. We studied whether endothelin-1 (FT-i)
and its receptor subtypes (ETAR, endothclin A type receptor; and ETBR,
B type receptor) were up-regulated in the glomerulus of a rat model of
mesangial proliferative glomerulonephritis induced by anti-thymocyte
serum (anti-Thy-i ON). A marked increase in preproET-i mRNA could
be demonstrated in glomerutar RNA 3 and six days after disease induction
(4.i- and 4.9-fold vs. day 0, respectively), corresponding to the time of
mesangial cell proliferation, to the time of macrophage infiltration into
glomeruli, and also to the time of increase in glomerular PDGF B-chain
mRNA expression. The localization of FT-I protein in the mesangial area
and along the inner aspect of the glomerular capillary wall was also
demonstrated by immunohistochemistry from day 3 and maximal at day 6.
The major source of the cells expressing FT-i in glomeruli appeared to be
mesangial cells, glomerular endothelial cells and monocyte/macrophages.
Furthermore, both gene and protein expression of FT-i were associated
with increased urinary excretion of FT-i. There was no increase in the
plasma ET-i immunoreactivity. Glomcrular expression of ETuR mRNA
increased in anti-Thy-i ON (1.5-fold vs. day 0 at day 3 after disease
induction, 3.6-fold at day 6 and 2.7-fold at day 10), but there was minimal
change in ETAR mRNA expression. These results suggest that pre-
proET-i mRNA, which is induced in anti-Thy-i GM, is linked primarily
with ETBR mRNA expression. Up-regulated expressions of both pre-
proET-1 mRMA and ET-i protein, and increased urinary FT-i excretion
in the proliferative phase of anti-Thy-I ON were dramatically suppressed
by complement depletion with cobra venom factor treatment, and these
ruled out the possibility that the change of FT-i might be from the direct
effect by anti-Thy-i antibody itself. In conclusion, there is an induction of
glomerular FT-i and FTBR gene transcription and FT-i protein synthesis
in rat mesangial proliferative glomerulonephritis. PreproET-1 mRNA
expression was closely associated with PDGF B-chain mRNA expression
and the up-regulation of FT-i expression may stimulate PDGF-dependent
mcsangial cell proliferation in anti-Thy-i nephritis. ET-i production in
glomeruli may allow an amplification of mesangial cell proliferation and
subsequent matrix expansion in this model.
Endothelin, a potent vasoeonstrietor, was isolated from cul-
tured porcine aortie-endothelial cells [I]. Subsequent studies have
demonstrated that endothelin-i (FT-i) has a wide diversity of
biologic actions [2]. In the kidney, FT-I stimulates mesangial cell
proliferation [3] in addition to multiple hemodynamic effects [4].
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Recent studies have demonstrated that resident glomerular cells,
including mesangial cells and glomerular epithelial cells, synthe-
size endothelins [5—8]. At least two FT receptor subtypes have
been cloned and sequenced [9, i0j, These two FT receptor
subtypes (A-type receptor, FTAR; and B-type receptor, ETBR)
are present in the glomerulus [lii and FT-I binds to both
receptors [9, 101. This suggests that FT-i may participate in
glomerular disease as an autoerine factor. Therefore, we designed
the present study to examine the expression of FT-i and its
receptors in the glomerulus in a rat model of mesangial prolifer-
ative glomerulonephritis induced by anti-thymoeyte antibody (an-
ti-Thy-i ON). This model is associated with a complement
dependent mesangiolysis that peaks at day 1, followed by mesang-
ial cell proliferation occurring two to seven days after disease
induction. This model was chosen because previous studies have
demonstrated the involvement of several growth factors, including
PDGF, basic FOE and TGF-j3, and because there is a marked
mesangial cell proliferation and matrix expansion [12—14].
Methods
Experimental protocol and disease model
Six groups of male Wistar rats (Nippon lkagaku Doubutsu,
Tokyo, Japan) weighing i80 to 200 g were studied: (a) normal
unmanipulated rats (day 0, N = 13); (b—d) Rats with anti-Thy-i
ON at 3, 6 and 10 days after disease induction (N 13 in each
group); and (e—f) Rats with anti-Thy-i ON (days 3 and 6) that
were complement depleted with cobra venom factor (CVF; Al =5
in each group). Animals were fed standard rat chow (Oriental
Yeast Co. Ltd., Tokyo, Japan). The disease was induced by a
single intravenous injection of goat aoti-rat thymocyte plasma
(ATS; gift from R.J. Johnson, University of Washington, Seattle,
WA, USA; 0.4 mI/iOU g body wt) as previously reported [12].
Complement depletion was achieved in five rats by the intraper-
itoneal injection of CVF (from Naja naja kaounthia, 30 U i.p.;
Sigma Chemical Co., St. Louis, MO, USA) in three divided
doses beginning 24 hours prior to injection of ATS with re-
peated daily injection (iO U i.p.) until sacrifice. Serum C3 levels
in the CVF-treated rats obtained at the time of injection of
ATS and at sacrifice three or six days later were <10% of baseline
(that is, pre-CVF injection) values as measured by radial immu-
nodiffusion [12].
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In each group, the rats were sacrificed at the specified times
mentioned above. Total RNA was extracted from the isolated
glomeruli of four rats in each group and Northern blot analysis
was performed using specific probes for preproET-i, ETAR,
ETBR, PDGF B-chain and 28S ribosomal RNA [9, 15—18].
Preparation of glomerular RNA was performed for two times on
different sets of animals. The kidney tissues from another five rats
in each group were also committed to histological examination.
The glomerular localization of ET-1 gene product was determined
by immunohistochemistry and immunofluorescence. In addition,
the number of proliferating glomerular cells or infiltrating mono-
cyte/macrophages into glomeruli was assessed by the number of
cells per glomerular cross section that stained for the proliferating
cell nuclear antigen (PCNA) or ED-i, respectively, as previously
described [12, 19].
Immunohistochemical staining for proliferating cells and
monocytelmacrophages
Kidney tissue from each rat was fixed in methyl Carnoy's
solution and 4 jm sections stained by the indirect immunoperox-
idase method [121. Primary antibodies included:
i9A2 (Coulter Immunology, Hialeah, Florida, USA), a murine
monoclonal antibody against human PCNA, which is an auxiliary
protein to DNA polymerase delta that is expressed in late Gi,
peaking during S phase, and extending to the M phase of the cell
cycle [20, 21].
ED-i (Chemicon International Inc., Temecula, California,
USA), a murine monoclonal IgG to a cytoplasmic antigen present
in monocytes, macrophages and dendritic cells.
For all staining, negative controls consisted of substitution of
the primary antibody with equivalent concentration of an irrele-
vant murine monoclonal antibody. Quantitation of proliferating
(PCNA+) cells and macrophages (ED-i+ cells) was performed
by examining, in a blinded fashion, all glomeruli containing more
than 20 discrete capillary segments each (range 21 to 36; mean
27.9 7.1) in each biopsy and enumerating the number of
positive cells per glomerular cross section.
Immunohistochemical and immunofluorescence staining for ET-1
Four micron sections of 4% paraformaldehyde fixed renal
tissues were processed by an indirect immunoperoxidase tech-
nique. Primary antibody was an IgG fraction of murine monoclo-
nal anti-ET against C-terminus of synthetic endothelin peptide,
and recognized ET-i and -3 (IBL, Tokyo, Japan). For all kidney
tissues, negative controls consisted of substitution of the primary
antibody with an irrelevant murine monoclonal antibody. For
evaluation of ET staining, each glomerulus was graded semiquan-
titatively. Each score reflected mainly changes in the extent rather
than intensity of mesangial matrix staining [22].
0 - Diffuse, very weak or absent mesangial matrix staining. No
localized increase of staining.
1 + - Diffuse, weak mesangial matrix staining with ito 25% of the
glomerular tuft showing focally increased staining.
2+ - 25 to 50% of the glomerular tuft demonstrating focal, strong
staining.
3+ - 50 to 75% of the glomerular tuft staining strongly in a focal
manner.
4+ - >75% of the glomerular tuft staining strongly.
For each tissue 28 to 37 glomerular cross sections containing
>20 discrete capillary segments (range 22 to 39; mean 29.1 5.4)
were evaluated by a blinded observer, and mean values per section
were calculated. Glomeruli with large microaneurysms replacing
more than half of the glomerular tuft, primarily seen at days 1 to
3 after disease induction, were excluded in this evaluation.
immunofluorescence detection of glomerular ET-1 was carried
out on 4 sections of frozen, previously unfixed kidney tissue
using an indirect immunofluorescence procedure. For the primary
antibody a rabbit polyclonal IgG to ET-1 against C-terminus of
synthetic endothelin peptide, which recognized only ET-1 (IBL,
Tokyo, Japan) was used followed by a FITC-labeled sheep
anti-rabbit IgG antibody (Tago, Burlingame, CA, USA). A direct
immunofluorescent staining was also done using FITC-labeled
anti-F(ab')2 of ET-1 (IBL). Glomerular cross sections were
graded semiquantitatively as described elsewhere [19]. Another
set of all sections were performed with DAB (diaminobenzidine)
enhancement using DAB enhancing solution (Vector Laborato-
ries, Burlingame, CA, USA).
Isolation of glomeruli and preparation of glomerular RNA
Glomeruli were isolated by differential sieving [23]. To preserve
the integrity and stability of the glomerular RNA all isolation
steps were done at 4°C using diethylpyrocarbonate (Sigma)
treated PBS, autoclaved or baked sieves and glassware and using
as little time as possible for the preparation. Less than 20 minutes
elapsed from nephrectomy to dissolution of the isolated glomeruli
in RNAz0IBR solution (Cinna/Biotecx Laboratories Inc., Hous-
ton, TX, USA). To affirm that the isolation procedure did not
select a subpopulation of glomeruli, glomeruli were isolated from
a kidney at three days after disease induction and histological
changes as well as the number of PCNA positive cells were
compared with those in a simultaneous tissue of the same kidney.
isolated glomeruli showed similar pathological changes to those
observed in the kidney tissue. Staining for PCNA revealed positive
cells in intact isolated glomeruli (16.3 3.1 per glomerulus, N
40), which was in the range observed in the renal tissue (17.8 1.6
PCNA positive cells/glomerular cross section).
Total RNA was extracted from isolated glomeruli from all
groups of rats with RNAz01BR following the manufacturer's
instructions as previously reported [19].
RNA gel electrophoresis and Northern blot analysis
Total glomerular RNA was denatured with formamide and
formaldehyde, and electrophoresed through a 1% agarose gel (15
jg RNA/lane), containing 2.2 M formaldehyde/0.2 M MOPS pH
7.0, transferred to a nylon membrane (Hybond N'' Amersham,
Arlington Heights, IL, USA) overnight by capillary blotting in 10
x SSPE (1 X SSPE = 0.18 M NaCl, 0.01 M NaH2PO4, 0.001 M
EDTA), and baked at 80°C for two hours. Examination of the
membrane under short UV light in the presence of ethidium
bromide demonstrated good resolution and integrity of the 28S
and 18S ribosomal bands.
DNA probe and hybridization conditions
The cDNA probes used for Northern blot analysis were as
follows:
(1) PreproET-1. An EcoRI fragment of rat preproET-1 from
cDNA clone PUC 118 of 2.0 kb was used to detect the 2.3 kb
transcript of preproET-i [15].
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(2) ETAR. Oligoprobe (antisense DNA) positioned between 5'
and 3' primer was synthesized. The sequence of 20 oligonucleo-
tide was 5'-CCCI1TGATFACCGCCA1TI'G-3' [17, 24, 251.
(3) ETBR. An Xbal fragment of rat ETBR from cDNA clone
PUC 118 of 2.0 kb was used to detect the 5.0 kb transcript of
ETBR [9].
(4) PDGF B-chain. Murine PDGF B-chain genomic DNA (a
326 bp fragment) was cloned into the SmaI site of the transcrip-
tion vector pGEM1 at a site between the SP6 and T7 promoters
(provided by Dr. Daniel F. Bowen-Pope, University of Washing-
ton, Seattle, WA, USA) [18].
(5) 28S ribosomal RNA. A bovine 280 bp cDNA probe was used
to detect 28S ribosomal RNA (provided by Dr. Luisa Iruela-
Arispe and Dr. Helene Sage, University of Washington) [16].
Probes of preproET-1, ETBR, PDGF B-chain and 28S ribo-
somal RNA were labeled with [a-32P]-deoxycytidine 5-triphos-
phate (3000 Ci/mmol, NEN Research Products, Tokyo, Japan) by
random primer extension. The synthetic oligonucleotide for
ETAR was end-labeled with [y-32P]-adenosine 5 '-triphosphate
(6000 Ci/mmol, NEN Research Products). Membranes were
prehybridized in a solution containing 50% (vol/vol) formamide, 5
X SSPE, 5x Denhardts, 0.1% SDS and 100 rg of salmon sperm
DNA per ml. Hybridization was performed with the same solu-
tion, to which 1 to 2 >< 106 cpm/ml of 32P-labeled eDNA or
oligoprobe was added, for 24 hours at 42°C. Blots were then
washed three times in 2 X SSPE, 0.1% SDS for five minutes each
at room temperature and then in 0.1 x SSPE, 0.1% SDS for
eDNA probes and 0.5 x SSPE, 0.1% SDS for oligoprobe at 42°C
to 60°C depending on stringency conditions required. After
drying, membranes were exposed to non-preflashed Kodak X-O
MAT film (Kodak, Tokyo, Japan) with enhancing screens at
—70°C. The obtained autoradiograms were read by linear densi-
tometry. (Electrophoresis Data CenterR, Helena Laboratories,
Beaumont, TX, USA) at 600 n. Some membranes were rehy-
bridized with additional probes (up to a maximum of 3x); these
membranes were stripped in 0.01 X SSPE, 0.5% SDS for 20
minutes at 95°C prior to rehybridization. All Northern analyses
were repeated two times with glomerular RNA preparations
obtained from different sets of animals.
Quantitation of mRNA
Obtained autoradiograms were read by linear densitometry
(see above) at 600 nM. Densitometiy readings were normalized for
equivalent amounts of 28S ribosonial RNA per lane as described
[19]. Values are expressed as optical density units relative to the
specific mRNA level observed in glomerular RNA from normal
rats.
Radioimmunoassay (RL4) of urinaty ET-1 and plasma ET-1
Production of antibody for ET-1 was as follows [26]: synthetic
ET-1 (Peptide Institute, Inc., Osaka, Japan) was conjugated to
bovine thyroglobulin (Sigma) using carbodiimide as a coupling
agent. The conjugate, emulsified with or without an equal volume
of complete Freund's adjuvant (Difco Lab., Detroit, MI, USA),
was injected intradermally at multiple sites on the back of
Japanese white rabbits. A total dose of 0.5 mg ET-1 in the
conjugate was administered to each animal over a period of 12
weeks at intervals of 3 to 28 days. They were bled 12 days after the
last immunization. One of the antisera suitable for RIA was
selected.
Table 1. Proliferating cells (PCNA-positive cells) and
monocyte/macrophages (ED-I positive cells) in glomerular cross
sections of normal rats and rats with anti-Thy-i
glomerulonephritis (GN)
Group N
PCNA-positive cells
per glomerular
cross section
ED-I positive cells
per glomerular
cross section
Normal controls 9 1.1 0.2 2.9 0.4
GN day 3 9 17.8 1.6° 12.7 0.6°
GN day 6 9 15.3 1.6" 6.3 0.3
ON day 10
GN day 3 + CVF
9
5
3.7 0.5°
1.6 0.56
3.1 0.3
3.8 1.16
GN day 6 + CVF 5 1.6 0.6° 2.7 0.7"
"p < 0.01 vs. normal
b P < 0.01 vs. GN day 3
P < 0.01 vs. ON day 6
Rats from all groups (5 rats in each group) were housed in
metabolic cages for 24 hours, and urine samples were collected.
Urine samples after extraction with Spe-C3 cartridges (J.T. Baker
Chemical Co., Phillipsburg, NJ, USA) [27] were subjected to RIA.
ET-1 RIA was performed essentially in the same manner as
reported using a antibody specific for ET-1 [271. Briefly, 0.1 ml
sample or standard ET-i (Peptide Institute, Inc.), 0.1 ml assay
buffer, and 0.1 ml anti-ET serum (final dilution: 1:300,000) were
incubated at 4°C for 20 hours, followed by the late addition of 0.05
ml '251-ET-1 (83 pmol/ml; specific activity 74 TBq/mmol; Amer-
sham International plc, UK), and further incubation at 4°C for 48
hours. The separation of bound from free ligands was performed
by the double-antibody/polyethylene glycol method [27].
Two milliliters of plasma was obtained at sacrifice from normal
rats (day 0, N = 5), and rats with anti-Thy-i GN at day 3 (N = 5),
day 6 (N = 5) and day 6 with CVF treatment (N = 5) were also
examined for ET-1 by RIA using the same protocol as above.
Statistics
All values are expressed as mean SD unless stated otherwise.
Statistical significance (defined as P < 0.05) was evaluated using
the Student's t-test or one way analysis of variance with modified
t-test performed using the Bonferroni correction [28].
Results
Glomerular cell proliferation and macrophage/monocyte
infiltration
Rats with anti-Thy 1 GN developed mesangiolysis followed by
cellular proliferation, as reported previously [29] (data not
shown). An increase in total cellularity was present by day 3 and
peaked at day 6 when there was a 38% increase in glomerular
cellularity as compared to normal rats. A marked increase in
PCNA positive cells was observed in glomeruli at day 3 (17.8 1.6
PCNA+ cells per glomerular cross section) and at day 6 (15,3
1.6). Thereafter proliferation slowly subsided (Table 1). In con-
trast, controls (day 0) showed no increase in total or proliferating
glomerular cells over the study period (1.1 0.2), and the lack of
glomerular cell proliferation was also observed in rats with
anti-Thy-i GN (days 3 or 6) that were complement depleted with
CVF (1.6 0.5 at day 3 and 1.6 0.6 at day 6). An increase in
ED-I positive monocyte/macrophages in the glomerulus was also
observed, peaking at day 3, and decreasing thereafter. Rats with
ni d3 d6 dlO dS d6
+CVF +CVF
dS d6 dlO d3 d6
÷CVF +CVF
ni d3 dO dlO d3 dO
÷CVF +CVF
ni dS dO dlO d3 dO
÷CVF +CVF
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Fig. 1. Northern analysis of total glomerular RNA (15 .ug/lane) obtained in
normal rats (ni), in rats with anti-Thy-i nephritis at day 3 (d3), day 6 (do),
day 10 (diO), and in rats with anti-Thy-i nephrif is that were complement
depleted with cobra venom factor at day 3 (d3+CVF) and day 6 (d6+CVF)
for the gene expressions of preproEndothelin-l (preproET-i), endothelin A
type receptor (ETAR), endothelin B type receptor (ETBR), PDGF B-chain
and and 28S ribosomal RNA (28S rRNA).
anti-Thy-i GN at day 3 or at day 6 with CVF treatment had
similar numbers of ED-i positive cells in the glomerulus as
compared to normal rats (3.8 1.1 at day 3 with CVF, 2.7 0.7
at day 6 with CVF vs. 2.9 0.4 at day 0, P = NS, respectively;
Table 1).
Table 2. Staining score for endothelin-1 in glomeruli by
immunohistochemistiy of normal (day 0) and in unmanipulated and
complement depleted (CVF treated) rats with mesangial proliferative
nephritis (anti-Thy-i GN)
Staining score for ET-1
DayO 0
Day 3 0.92 0.lla
Day6 2.14±0.11k'
Day 10 1.27 0.29
Day3+ CVF 0
Day6+ CVF 0
Glomerular expression of preproET-1 mRNA was increased at
day 3 (4.1-fold vs. day 0) and day 6 (4.9-fold vs. day 0), corre-
sponding to the time of glomerular cell proliferation and mono-
cyte/macrophage infiltration in the glomerulus. At day 10 pre-
proET-1 mRNA expression decreased (1.8-fold vs. day 0) in
-5 0 kb parallel with a decrease in glomerular cell proliferation and
monocyte/macrophage infiltration. In contrast, glomerular ETBR
mRNA expression increased oniy slightly at day 3 (1.5-fold vs. day
0). Enhanced expression of ETBR mRNA peaked at day 6
(3.6-fold vs. day 0) and was maintained to day 10 (2.7-fold vs. day
0). However, the up-regulation of both preproET-1 and ETBR
mRNA expressions in rats at days 3 or 6 after disease induction
were suppressed with CVF treatment (1.3-fold at day 3 and
1.2-fold at day 6 vs. day 0 in preproET-1, and 1.0-fold at day 3 and
3.5 kb 1.2-fold at day 6 vs. day 0 in ETBR). Glomerular mRNA express-
sion for ETAR was not significantly affected in anti-Thy-i GN.
ETAR mRNA expression at day 3, day 6, day 10, and day 3 or day
6 with CVF treatment was 1.2-, 1.3-, 1.1-, 1.2-, 1.2-fold versus day
0, respectively. Similar to our previously report [12], glomerular
PDGF B-chain mRNA expression was up-regulated in prolifera-
tive phase in this model (6.1-fold at day 3 and 5.9-fold at day 6, but
only 1.4-fold at day 10 vs. day 0) and complement depletion
-28S
completely suppressed the expression both at day 3 (1.2-fold) and
at day 6 (1.3-fold). Thus, both ET-1 and PDGF B-chain gene
expressions were associated with complement dependent active
glomerular cell proliferation in anti-Thy-i GN.
Expression and localization of endothelin-1 protein in
the glomerulus
Table 2 summarizes the results of staining score for ET-1 in
glomeruli from rats with anti-Thy-i GN. There was no positive
staining for ET in the glomerulus by immunohistochemistry in
normal rats (day 0) (Fig. 2A). Increased expression of ET protein
was demonstrated in the mesangium after day 3 (staining score =
0.92 0.11) and staining intensity in the glomerulus reached a
maximum at day 6 after disease induction (staining score = 2.14
0.11; Fig. 2B). Positive staining for ET on the inner surface of
glomerular capillaiy walls was also demonstrated at day 6, consis-
tent with a glomerular endothelial cell location (Fig. 2C). Staining
intensity of ET by immunohistochemistry decreased at day 10
(staining score = 1.27 0.29). By immunofluorescence staining,
ET-1 was localized to mesangial areas as well as to the glomerular
capillary wall at day 6 (Fig. 3). There was no difference in staining
intensity or localization of ET-1 between indirect and direct
immunofluorescence procedure (data not shown). There was also
positive staining for ET-1 in the collecting duct and in the inner
prepro ET-1 -2.3 kb
-4.2 kb P < 0.01 vs. day 0ETAR
ETBR
PDGF-B
28S rRNA
Glomerular gene expressions of preproET-1, ETAR, ETBR and
PDGF B-chain
Figure 1 summarizes the time course of changes in mRNA
expression for preproET-1, ETAR, ETuR, PDGF B-chain and 28S
ribosomal RNA in glomeruli from rats with anti-Thy-i GN.
-r &
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Fig. 3. Indirect immunofluorescence staining for endothelin-i with the
polyclonal antibody in rat with anti-Thy-i glomendonephritis at day 6 after
disease induction (x400). Positive immunofluorescence staining to endo-
thelin-1 was shown in the mesangial area and the inner surface of
glomerular capillary lumen.
Measurement of urinary ET-1 immunoreactivily
The minimum detectable quantity in the present ET-1 RIA was
0.4 pg/tube (97.5% confidence), and the 50% intercept was 9
pg/tube. Figure 4 shows results of urinary ET-1 immunoreactivity
by RIA. The urinary excretion of ET-1 in normal rats (day 0) was
23.0 15.7 pg/24 hr. The urinary ET-1 excretion was significantly
increased at day 3 (97.4 56.6, P < 0.05 vs. day 0), at day 6 (227.0
90.6, P < 0.01 vs. day 0) and at day 10 (172.9 72.6, P < 0.01
vs. day 0). The urinary ET-1 excretion in rats with CVF treatment
at day 3 or day 6 after disease induction (38.6 21.8 at day 3 and
36.6 6.7 at day 6) was significantly suppressed in comparison
with the value of the days 3 or 6, respectively (both were P < 0.01)
(Fig. 4).
Measurement of plasma ET-i immunoreactivily
Fig. 2. immunostaining for the endothelin protein in normal and anti-Thy i
glomerulonephritis rats. Olomeruli from normal rats were completely
negative for the endothelin ptotein (A), although some tubules were
positive. In mesangial proliferative nephritis, there was a significant
increase in cells positive for the endothelin protein within the mesangial
regions of the glomerulus at day 6 after disease induction (B). A positive
staining for endothelin was also observed in the inner surface of glomer-
ular capillary liumen at day 6 after disease induction (arrows) (C). (A.
Immunoperoxidase, 400X; B. Immunoperoxidase, 600X; C. Immunoper-
oxidase with DAB enhancing, 1000X).
surface of small arteries; however, no apparent difference was
demonstrated between normal and diseased rats. Positive staining
for ET in the giomerulus was not demonstrated in rats with
complement depletion by CVF at day 3 or day 6 after disease
induction.
RIA for measurement of plasma ET-1 was performed on 20
samples (5 samples in each from day 0, 3, 6 and day 6 with CVF)
in total. The minimum detectable quantity was 0.6 pg/mI. Nine
samples were below 0.6 pg/mI and there was no difference in the
plasma ET-1 immunoreactivity in four groups rats examined: day
0 (below 0.6, below 0.6, 1.1, 1.5 and 2.8 pg/ml), day 3 (below 0.6,
below 0.6, below 0.6, below 0.6 and 1.6 pg/mi), day 6 (below 0.6,
below 0.6, 1.5, 1.5, 3.2 pg/mI) and day 6 with CVF (below 0.6, 1.1,
1.5, 1.5, 1.5 pg/nil).
Discussion
ET causes activation of phospholipase C and increases c-fos
proto-oncogene expression in rat glomerular mesangial cells via
specific binding sites [3, 30], and acts as a potent mitogen for rat
mesangial cells, in addition to its hemodynamic effects [4]. Both
rat and human mesangial cells produce ET-I [6, 7, 17, 25], and
also express ETAR and EToR in vitro [25, 31]. This suggests that
ET-1 may function as an autocrine growth factor for mesangial
cells, similiar to that which has been shown for PDGF both in vitro
[32] and in vivo [12, 29].
PDGF is one of the most potent mitogens for cultured mesang-
ial cells [32, 33] and is expressed in the glomeruli of rats with
anti-Thy-I nephritis [12, 29]. Several studies suggest that PDGF
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Fig. 4. Measurement of urinary endothelin-1 immunoreactivily by RL4
(pg/24 hr). Endothelin-1 excretion into the urine significantly increased
from day 3 to day 10 after disease induction and was maximum at day 6.
In nephritic rats with complement depletion by cobra venom factor, there
was no increase in urinary ET-1 excretion at day 3 and 6 after disease
induction and both were significantly low compared to those of unma-
nipulated nephritic rats at the same point after disease induction. p <
0.05 versus day 0; **p < 0.01 versus day 0; ¶P < 0.01 versus day 3; ¶P <
0.01 versus day 6.
has a central role in proliferative glomerulonephritis [34]. ET-1
stimulates PDGF release associated with the enhanced induction
of mRNAs encoding PDGF A- and B-chain from cultured human
mesangial cells [35]. PDGF also stimulates ET-i release from rat
mesangial cells, and inhibition of ET-1 reduces the proliferative
effects of PDGF on mesangial cells [36]. These reports suggest
that ET-i may act on mesangial cells in an autocrine or paracrine
manner to regulate glomerular cell proliferation in glomerulone-
phritis. However, there is no report demonstrating ET-i expres-
sion in the glomerulus associated with proliferative glomerulone-
phritis in vivo.
In this study, we have found increased gene expressions of ET-1
and ETBR in glomeruli from rats with mesangial proliferative
nephritis induced by anti-thymocyte antibody. The increased
glomerular expression of preproET-1 mRNA correlated with the
period of active glomerular cell proliferation as defined by PCNA
immunostaining. The expression of ET-i protein in the mesangial
areas and along the inner aspect of the glomerular capillary wall
was also demonstrated during the proliferative phase. The expres-
sion of preproET-1 mRNA preceded ET-1 protein expression.
Thus, in rat mesangial proliferative glomerulonephritis there is an
induction of ET-i gene transcription and ET-i protein synthesis.
We have reported the up-regulation of glomerular PDGF B-chain
mRNA expression in the proliferative phase of anti-Thy-i GN
[121, and in the present study we have demonstrated that glomer-
ular ET-i mRNA expression increased in parallel with the
up-regulation of PDGF B-chain mRNA in glomeruli in this
model. This evidence strongly suggests that both PDGF and ET-1
are tightly associated with glomerular cell proliferation.
Glomerular cell proliferation in anti-Thy-i GN was comple-
ment dependent [12, 29] and up-regulation of both preproET-1
mRNA and ET-1 protein and the increased urinary excretion of
ET-1 in the proliferative phase of anti-Thy-i GN were dramati-
cally inhibited by complement depletion with CVF. These results
ruled out the possibility that changes of preproET-1 mRNA and
ET-1 protein might be from the direct stimulation by anti-Thyl
antibody itself.
The major source of the cells expressing ET-1 in glomeruli
appeared to be mesangial cells and glomerular endothlelial cells
as suggested by the staining pattern with the anti-ET antibody
(by immunohistochemistry or immunofluorescence). However,
changes of both preproET-1 mRNA expression and PCNA posi-
tive cells in the glomerulus also correlated with the monocyte/
macrophages infiltration into the glomeruli. Macrophages can
synthesize and secrete endothelins [37]. Nakamura et al reported
that 95% of patients with IgA nephropathy had increased ET-1
mRNA expression in peripheral blood monocytes and this expres-
sion was positively correlated with urinary protein excretion and
histological severity of glomeruli [38]. Monocyte/macrophages, in
addition to mesangial cells and glomerular endothelial cells, may
participate in the up-regulation of ET-i expression in the prolif-
erative phase of this model. In the present study, we demonstrated
the increased urinary excretion of ET-1 observed in parallel with
glomerular cell proliferation, and there was no difference in
plasma ET-i immunoreactivity between normal and diseased rats.
Therefore, the majority of urinary ET-i was thought to originate
from the kidney itself, presumably due to the release of ET-1 from
resident glomerular cells or infiltrating monocyte/macrophages
within the glomerulus.
Many experimentally-induced glomerular diseases that result in
glomerular cell proliferation are characterized by an influx of
platelets into glomeruli in the very early phase [19, 39]. In a rat
model of subendothelial immune complex nephritis that histolog-
ically resembles diffuse proliferative lupus nephritis, the platelet
can be shown to be activated, and many are degranulated and
adherent to areas of the glomerular basement membrane where
the endothelium has been denuded [39]. Johnson et al clearly
demonstrated an early platelet accumulation in the glomerulus
followed by mesangial cell proliferation and the significant reduc-
tion of glomerular cell proliferation by the depletion of platelets
with an anti-platelet antibody in the anti-Thy-i model. In the
present study, an early accumulation of platelets in the glomerulus
may be important in the enhanced expression of FT-i mRNA
because platelets can stimulate both preproET-I mRNA expres-
sion and ET production in cultured bovine and human endothelial
cells [40]. TGF-p may be also important in this process because
TGF-p is a potent inducer of the ET gene [7] and the glomerular
expression of TGF-f3 is up-regulated in the anti-Thy-i model [41,
42]. The mitogenic effects of angiotensin II on mesangial cells also
appears to be mediated through mesangial cell FT-i production
[43]. Furthermore, insulin potentiates the mitogenic effect of Ang
II through stimulation of ET [43]. Thus, many factors mentioned
above may contribute to the up-regulation of ET-1 expression in
proliferative glomerulonephritis.
In the present study, glomerular expression of both preproET-1
mRNA and ETBR mRNA increased during proliferative phase,
whereas minimal change was observed in ETAR mRNA expres-
sion. It is now known that there are at least two receptors for
endothelin, with ETAR having greater affinity for the ET-i
isoform as compared to ET-2 and ET-3, whereas ETBR binds
ET-1, ET-2, and ET-3 with equal affinity [9]. Both ETAR and
ETBR are present within the glomerulus [11, 44]. Endothelial cells
contain primarily the ETBR, while smooth muscle cells contain
some combination of ETAR and ETBR. We have previously
shown that the regulation of each one of the receptor subtypes is
independent, that the interaction of the ligand with each one of
the receptors is specific, and that the function of each one of the
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receptors is also unique [24, 25]. Recently, we investigated the
interaction between endothelin ligand and each one of the
receptor subtypes in mesangial cells which possess both receptor
types and have shown that ET-1 has a very profound effect on its
own gene expression, increasing the mRNA levels by more than
400%. Furthermore, while ET-1 did not change the expression of
the ETAR subtype, a profound increase in the ETaR mRNA
expression was observed. Additional experiments revealed that
these observations are causally linked. Treatment with a specific
ETuR, but not ETAR antagonist, abolished the increase in ET
gene expression [17, 1• Therefore, ETBR mediates the auto-
stimulation of endothelin production, and may amplify the ad-
verse effects mediated by this powerful peptide. In anti-Thy-i GN,
the auto-induction of ET-i may also result in part from the
increase in the ETnR subtype, and may underlie the potent and
persistent effects of ET-i.
Remuzzi et al demonstrated the participation of ET in rats with
extensive renal mass reduction, a model of progressive glomeru-
losclerosis [46—49J. They demonstrated the progression of renal
disease after renal ablation was associated with both an increased
renal ET-1 gene expression and increased urinary excretion of
ET-i [46—481. Furthermore, they shOwed that an endothelin
receptor antagonist reduced the abnormal permeability to pro-
teins, limited glomerular injury and prevented renal function
deterioration in the same renal ablation model as above [501.
Thus, ET-1 is a possible mediator of renal disease progression
characterized by glomeruloselerosis. This hypothesis was rein-
forced by the correlation of glomerular ET gene expression with
progression of glomerular sclerosis in rats with puromycin ami-
nonueleoside nephrosis [51j and in streptozotocin-induced dia-
betic rats [52]. Furthermore, a coordinate expression of ET-1 with
TGF-3 in the kidney with cpklcpk mice also suggests an important
role of ET-1 in renal disease progression [53]. Nakamura and his
colleagues have also shown that endothelin receptor antagonists
decrease the expression of extraeellular matrix components, met-
alloproteinases and tissue inhibitor of metalloproteinase-1 in the
kidneys of murine lupus nephritis [54].
In addition to the possible role of ET on the progression of
glomeruloselerosis, our results suggest that ET-1 generation in
glomeruli may be important in glomerular cell proliferation,
which precedes the accumulation of extracellular matrix protein in
glomeruli, in the anti-Thy-i nephritis. In conclusion, there is an
induction of both ET-1 and ETuR gene transcription and ET-i
protein synthesis in rat mesangial proliferative glomerulonephri-
tis. ET-i production in glomeruli may allow autoerine or para-
crine mediated amplification of mesangial cell proliferation and
subsequent matrix expansion in this model. Although there are
very limited data on humans, increased urinary excretion of ET-1
was demonstrated in patients with chronic progressive nephrop-
athies, such as membranous proliferative glomerulonephritis, IgA
nephropathy, minimal change nephrotic syndrome, focal glomer-
uloselerosis and lupus nephritis [55]. Further studies are needed
to clarify the relationship between abnormal ET-1 generation and
glomerular cell proliferation/glomeruloselerosis in human glomer-
ular diseases, and the effect of inhibition of ET-1 by specific
receptor blockade must be considered as one of the possible
therapies for human glomerular diseases.
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